ClinicalTrials.gg
CompletedNCT06299410Updated Sep 25, 2026

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

A Phase 1 interventional study of ITI-1284 10 mg and ITI-1284 20 mg in Healthy Volunteers, sponsored by Intra-Cellular Therapies, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.

Read the detailed description

This study consists of up to 3 sequential parts. Part A will evaluate the D2 receptor occupancy for ITI-1284 at three dose levels. Part B will evaluate the 5HT-2A receptor and SERT occupancy for ITI-1284 at one dose level. Part C will evaluate the late postdose receptor occupancy of ITI-1284 on the D2 or 5-HT2A receptor at one dose level.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.

First submitted before Intra-Cellular Therapies, Inc. became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between 18 and 55 years old (inclusive);
  • inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;
  • Willingness to remain in the hospital research unit for the duration of the inpatient period.

Exclusion criteria

Exclusion Criteria:

  • abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, gastrointestinal, pulmonary, endocrinologic, hematologic, or immunologic disease or history of ;
  • Clinically significant abnormal findings in vital sign assessments, supine SBP > 140 mmHg or \< 90 mmHg, or supine DBP >90 mmHg or \< 50 mmHg or supine pulse rate > 100 bpm or \< 45 bpm at Screening;
  • History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;
  • Any condition which would preclude MRI or PET/CT examination (eg, implanted metal, claustrophobia, unable to fit in PET/CT or MRI scanners);
  • based on any previous MRI or the study MRI performed prior to the baseline PET/CT scan.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Cohort A1: 10 mg ITI-1284

    Radioligand: \[11C\]-raclopride

    Drug: ITI-1284 10 mg

  • Experimental
    Cohort A2: 20 mg ITI-1284

    Radioligand: \[11C\]-raclopride

    Drug: ITI-1284 20 mg

  • Experimental
    Cohort A3: 30 mg ITI-1284

    Radioligand: \[11C\]-raclopride

    Drug: ITI-1284 10 mg · Drug: ITI-1284 20 mg

  • Experimental
    Cohort B1: 20 mg ITI-1284

    Radioligand: \[11C\]-MDL100907

    Drug: ITI-1284 20 mg

  • Experimental
    Cohort B2: 20 mg ITI-1284

    Radioligand: \[11C\]-DASB

    Drug: ITI-1284 20 mg

  • Experimental
    Cohort C1: 20 mg ITI-1284

    Radioligand: \[11C\]-raclopride or \[11C\]-MDL100907

    Drug: ITI-1284 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. % Receptor occupancy

    Percent change of binding potential from baseline

    Time frame: Day 1

Secondary outcomes

  1. Pharmacokinetics: AUC0-t

    Area under the plasma drug concentration-time curve (AUC) from time zero to the last measurable concentration

    Time frame: Day 1

  2. Pharmacokinetics: Cmax

    Maximum plasma concentration

    Time frame: Day 1

  3. Pharmacokinetics: Tmax

    Time of maximum plasma concentration

    Time frame: Day 1

  4. Percentage of subjects with treatment-emergent adverse events

    Time frame: Up to 30 days after the dose of study drug

  5. Change from baseline in ECG QT interval

    Time frame: Day 3

  6. Change from baseline in aspartate aminotransferase

    Time frame: Day 3

  7. Change from baseline in alanine aminotransferase

    Time frame: Day 3

07

Study locations

1 site
  • Yale University School Of Medicine
    New Haven, Connecticut 06519, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Aug 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Apr 11, 2024
Primary completionActual
Aug 18, 2026
CompletionActual
Aug 18, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06299410
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Apr 11, 2024
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026
Last update
Sep 25, 2026

Study contacts

Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deulumateperone

Start the discussion